A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
Completed · Phase 1 · NCT06186622
Conditions: Healthy, Obese, Overweight
At a glance
- Research payments reported, 2025
- $142,448
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Orforglipron (drug), Simvastatin (drug), Digoxin (drug), Rosuvastatin (drug), Acetaminophen (drug), Midazolam (drug), Sodium Bicarbonate (drug)
- Dates
- Started 2024-01-02; completion 2024-07-10
- Results posted
- Yes
The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that enters the bloodstream and how long it takes the body to eliminate them when administered orally in healthy overweight and obese participants. In addition, the effect of the orforglipron tablet on the amount of simvastatin that enters the bloodstream and how long it takes the body to eliminate it will be evaluated. The study will also assess the effect of sodium bicarbonate when administered alone with simvastatin versus orforglipron capsule containing sodium bicarb…
From ClinicalTrials.gov, last updated 2026-05-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $142,448 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $91,367
- Covance Clinical Research LP Dallas $51,081
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.